The independent pharmacy lobby is urging state legislatures to enact new legislation targeting pharmacy benefit managers (PBMs) that would increase fees and/or add surcharges to transactions with pharmacies. This is based upon two arguments: 1) that independent pharmacies are becoming
In case you missed it, Ike Brannon, health care economist and senior fellow at the Jack Kemp Foundation, published a new white paper, “Recently Proposed Federal and State Legislation To Constrain Pharmacy Benefit Managers Would Not Reduce Drug Costs,” in
(Washington, D.C.) — As prescription drug spending is poised to reach as much as $5 trillion during the next decade, new data find that pharmacy benefit managers’ (PBMs’) proven cost savings and patient care management tools should reduce prescription drug
Proponents of policies targeting pharmacy benefit companies ignore the costly repercussions of undermining pharmacy benefit managers’ (PBMs) ability to secure savings that enable health plan sponsors to offer quality, affordable prescription drug benefits. Proposals being pushed to “lower drug costs” that
Most state Medicaid programs have predominantly transitioned the prescription drug benefit to the managed care setting, through which Medicaid managed care organizations (MCOs) and their contracted PBMs collaborate using their prescription drug management and broader care coordination and integration tools.
In case you missed it, former U.S. Senator Pat Toomey (R-PA) warns Republican policymakers against passing unvetted and disastrous policies targeting pharmacy benefits being debated in Washington, in a new op-ed published in The Washington Times. Toomey writes: “Giant, must-pass
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today is announcing new staff additions to the Federal Affairs, State Affairs, Strategic Communications, and Industry Relations departments. “I want to welcome Jocelyn Wiles, Heather Cascone, Mike Baldyga, and Kayla Firriolo to PCMA’s
In case you missed it, a new report from health policy researcher Alex Brill, founder and CEO of Matrix Global Advisors and former policy director and chief economist for the U.S. House Committee on Ways and Means, “Rebates and Drug
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Administration’s final Medicare Part D rule: “We share the administration’s goal of reducing prescription drug costs in Medicare. We are pleased with
In case you missed it, the National Institute for Public Employee Health Care Policy recently released a report, “How Public Sector Health Care Purchasers Are Addressing Rising Drug Costs.” According to the report, “Through pooled purchasing organizations, employers in the
©2024 PCMA. All Rights Reserved.
